Skip to main content
Fig. 5 | Genome Medicine

Fig. 5

From: CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial

Fig. 5

Gene mutations and treatment response/survival outcomes. a Relation between treatment response (including complete response, partial response, and no response) and gene mutation profile. bd Kaplan-Meier curves showed progression-free survival (upper panel) and overall survival (lower panel) of PTCL patients, according to the mutation status of CREBBP (b), IDH2 (c), and KMT2D (d)

Back to article page